This past week saw the last three IPOs of 2016 raise $735 million. IPO investors were stubborn until the end, as all three had to price at large discounts to public peers and below expectations. After hitting all time highs earlier in the week, markets...read more
TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, raised $36 million by offering 2.3 million shares at $15.50, a 14% discount to its Brussels-traded shares. TiGenix plans to list on the Nasdaq under the symbol...read more
Three companies are set to close out the 2016 IPO class in the upcoming week. Hotel search aggregator trivago, oil and gas E&P Wildhorse Resource Development and stemcell therapy...read more
TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, announced terms for its IPO on Monday. The Leuven, Belgium-based company is currently traded on the Euronext Belgium under ticker symbol TIG and is planning...read more
US IPO Weekly Recap: trivago leads final 3 IPOs of 2016 with an 8% return
This past week saw the last three IPOs of 2016 raise $735 million. IPO investors were stubborn until the end, as all three had to price at large discounts to public peers and below expectations. After hitting all time highs earlier in the week, markets...read more
TiGenix prices US IPO at $15.50, a 14% discount to Brussels-traded shares
TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, raised $36 million by offering 2.3 million shares at $15.50, a 14% discount to its Brussels-traded shares. TiGenix plans to list on the Nasdaq under the symbol...read more
US IPO Week Ahead: 3 deals lined up to close out 2016 IPO market
Three companies are set to close out the 2016 IPO class in the upcoming week. Hotel search aggregator trivago, oil and gas E&P Wildhorse Resource Development and stemcell therapy...read more
TiGenix, a Belgian stem cell biotech, sets terms for $53 million IPO
TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, announced terms for its IPO on Monday. The Leuven, Belgium-based company is currently traded on the Euronext Belgium under ticker symbol TIG and is planning...read more